Cellply wins an H2020 SME Instrument Phase 1 grant
Bologna (Italy) – Bruxelles (Belgium), 20 October 2016
Cellply has recently been awarded by the European Commission as winner of a SME Intrsument Phase 1 grant within the Horizon 2020 programme. The ONCOSMART (ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics) project aims at developing an innovative platform for precision medicine, able to profile each cancer patient by analyzing how one or multiple candidate drugs interact with patient’s cells. The innovative test works by extracting a tumor sample and loading it in the platform readily after sampling, while cells are still alive. The ability of the drug to kill tumor cells is then analyzed and personalized response profiles are created. The platform, consisting of a lab-on-a-chip embedded in disposable cartridge, an analytical instrument and a diagnostic software, provides a result in 24 hours and aims at guiding clinicians in selecting the optimal therapy on a patient-by-patient basis and at supporting drug development companies during clinical development of new drugs. The project will allow Cellply to perform a feasibility study, explore business opportunities and regulatory issues/opportunities, identify a supply chain and set the basis for the development of a new in-vitro diagnostic (IVD) platform.